The conversation around weight management in the Philippines is shifting—from quick fixes and judgments about willpower toward long-term health, medical guidance and a more individualized approach.
That was the central message of “Live Lighter,” a Tatler House Dialogues event held in partnership with Novo Nordisk, where three medical experts discussed obesity, healthy living and the growing complexity of weight-management advice.
The discussion comes as obesity becomes an increasingly important public-health concern. In Singapore, for example, the Ministry of Health reported that obesity among residents rose from 10.5% in 2019–2020 to 12.7% in 2023–2024, highlighting the wider regional challenge surrounding weight-related health.
Doctors: The number on the scale isn’t the whole story
The Tatler forum featured Dr Maricar Esculto-Khan of Makati Medical Center, Dr Rosa Sy of Cardinal Santos Medical Center and Dr Jaycy Violago-Olivarez, founder and CEO of healthcare platform Eluvo.
Their message was straightforward: successful weight management shouldn’t be reduced to a single number.
Violago-Olivarez emphasized that health needs can change throughout a person’s life. What may be appropriate for someone in their 20s may not be appropriate for someone in their 60s.
Esculto-Khan similarly stressed that a sustainable approach should allow people to continue functioning normally in their daily lives rather than relying on extreme restriction.
Obesity is more complicated than “just eat less”
One of the major themes of the discussion was the changing medical understanding of obesity.
The doctors pointed to factors including genetics, family history, biology and lifestyle as contributors to weight-related health.
That doesn’t make diet and physical activity irrelevant. Rather, the panel argued that lifestyle changes may sometimes need to be combined with professional medical care depending on an individual’s circumstances.
Novo Nordisk’s Philippine “Live Lighter” campaign similarly promotes a shift away from treating obesity simply as an issue of personal responsibility and toward understanding it as a complex, chronic condition influenced by biological, environmental and other factors.
There is no universal weight-management formula
Perhaps the most important takeaway from the discussion is that there is no one-size-fits-all treatment.
Dr Sy said treatment decisions should consider both effectiveness and safety, while care should be individualized according to a patient’s medical condition, preferences and goals.
The panel also emphasized the importance of continuing medical follow-up when treatment is used.
That distinction matters because social media has increasingly turned weight loss into a highly simplified conversation—often centered around dramatic transformations, restrictive diets or medications presented without proper medical context.
The doctors’ message was considerably less glamorous but more practical: understand your health, seek qualified advice and choose an approach that can be sustained.
Novo Nordisk’s growing role in the Philippine obesity conversation
The event is part of a broader effort by Novo Nordisk Philippines to change how obesity is discussed in the country.
In April 2026, the company launched its Live Lighter movement in the Philippines alongside the introduction of Wegovy (semaglutide) for obesity management. Independent Philippine reports including ABS-CBN News and BusinessMirror reported on the launch.
The company says the initiative is intended to bring healthcare professionals, patient advocates, media and other stakeholders into a more evidence-based conversation about obesity.
Importantly, Wegovy is a prescription medicine, and treatment decisions should be made with a qualified healthcare professional rather than based on social-media trends or self-diagnosis.
A major health conversation—but with an important caveat
The “Live Lighter” discussion reflects a genuine shift in how obesity is increasingly discussed in medicine: as a condition that can involve multiple biological and environmental factors rather than simply a question of willpower.
But because the event was produced in partnership with Novo Nordisk, readers should also recognize that the conversation sits within a pharmaceutical company’s broader obesity-awareness and treatment strategy. The medical points should therefore be considered alongside independent clinical guidance and evidence.
There is also an important international regulatory footnote. In February 2026, the US FDA said a Novo Nordisk television advertisement for the pill version of Wegovy contained false or misleading claims, particularly suggestions that “live lighter” implied additional weight loss or benefits beyond physical weight loss that had not been demonstrated. Novo Nordisk said it was responding to the regulator’s concerns.
That does not invalidate the Philippine Live Lighter event or mean Wegovy itself is unsafe. It does, however, reinforce why claims about weight-loss treatments should be evaluated carefully and why prescription medicines should be used under medical supervision.
The bigger message: health shouldn’t be reduced to a before-and-after photo
The discussion ultimately points to a broader change in wellness culture.
Weight management is increasingly being framed around health, quality of life and sustainable habits, rather than simply achieving a particular number on the scale.
For people concerned about their weight or related health risks, the most important next step isn’t necessarily another viral diet or social-media hack.
It may simply be having an informed conversation with a healthcare professional.
WWC ONE MEDIA J.M.D
Leave a Reply